Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21
Dae-Seok Kim, Cristel V. Camacho, Anusha Nagari, et al.
Molecular Cell (2019) Vol. 75, Iss. 6, pp. 1270-1285.e14
Open Access | Times Cited: 214

Showing 1-25 of 214 citing articles:

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González‐Martín, Bhavana Pothuri, Ignace Vergote, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 25, pp. 2391-2402
Open Access | Times Cited: 1778
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Ruixue Huang, Ping‐Kun Zhou
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 810
PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 525
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose, Joshua T. Burgess, Kenneth J. O’Byrne, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 515
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Jian Kang, Natalie Brajanovski, Keefe T. Chan, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 258
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms
Dan Huang, W. Lee Kraus
Molecular Cell (2022) Vol. 82, Iss. 12, pp. 2315-2334
Open Access | Times Cited: 159
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim, Cristel V. Camacho, W. Lee Kraus
Experimental & Molecular Medicine (2021) Vol. 53, Iss. 1, pp. 42-51
Open Access | Times Cited: 131
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
Ruifang Dong, Miaolin Zhu, Mingming Liu, et al.
Pharmacological Research (2021) Vol. 167, pp. 105583-105583
Closed Access | Times Cited: 127
snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology
Zhenghao Huang, Yuping Du, Jing-tao Wen, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 118
p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways
Mikael S. Lindström, Jiří Bártek, Apolinar Maya‐Mendoza
Cell Death and Differentiation (2022) Vol. 29, Iss. 5, pp. 972-982
Open Access | Times Cited: 89
Cellular functions of eukaryotic RNA helicases and their links to human diseases
Katherine E. Bohnsack, Soon Yi, Sarah Venus, et al.
Nature Reviews Molecular Cell Biology (2023) Vol. 24, Iss. 10, pp. 749-769
Closed Access | Times Cited: 67
PARP1 associates with R-loops to promote their resolution and genome stability
Natalie Laspata, Parminder Kaur, Sofiane Y. Mersaoui, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 5, pp. 2215-2237
Open Access | Times Cited: 50
Poly(ADP-ribose): A Dynamic Trigger for Biomolecular Condensate Formation
Anthony K. L. Leung
Trends in Cell Biology (2020) Vol. 30, Iss. 5, pp. 370-383
Open Access | Times Cited: 130
PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis
Dae-Seok Kim, Sridevi Challa, Aarin Jones, et al.
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 302-320
Open Access | Times Cited: 122
PARPs in lipid metabolism and related diseases
Magdolna Szántó, Rebecca Gupte, W. Lee Kraus, et al.
Progress in Lipid Research (2021) Vol. 84, pp. 101117-101117
Open Access | Times Cited: 102
Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers
Sridevi Challa, B.R. Khulpateea, Tulip Nandu, et al.
Cell (2021) Vol. 184, Iss. 17, pp. 4531-4546.e26
Open Access | Times Cited: 67
Identifying Poly(ADP-ribose)-Binding Proteins with Photoaffinity-Based Proteomics
Morgan Dasovich, Morgan Q. Beckett, Scott Bailey, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 8, pp. 3037-3042
Open Access | Times Cited: 63
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Shuangying Li, Liangliang Wang, Yuanyuan Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation
Chuanchao Zhang, Bo Zhou, Feng Gu, et al.
Molecular Cell (2022) Vol. 82, Iss. 7, pp. 1297-1312.e8
Open Access | Times Cited: 62
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, et al.
European Journal of Cancer (2021) Vol. 149, pp. 134-152
Closed Access | Times Cited: 56
DDX18 prevents R-loop-induced DNA damage and genome instability via PARP-1
Wen-Ling Lin, Jung-Kuei Chen, Xuemei Wen, et al.
Cell Reports (2022) Vol. 40, Iss. 3, pp. 111089-111089
Open Access | Times Cited: 42
Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma
Hongjun Xie, Muqi Shi, Yifei Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
Secondary structures in RNA synthesis, splicing and translation
Ilias Georgakopoulos-Soares, Guillermo E. Parada, Martin Hemberg
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 2871-2884
Open Access | Times Cited: 40
A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer
Ge Li, Shanshan Lin, Zelei Yu, et al.
Biochemical Pharmacology (2022) Vol. 206, pp. 115329-115329
Closed Access | Times Cited: 40
PARPs and ADP-ribosylation: Deciphering the complexity with molecular tools
Morgan Dasovich, Anthony K. L. Leung
Molecular Cell (2023) Vol. 83, Iss. 10, pp. 1552-1572
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top